Last reviewed · How we verify

Estradiol patch

University of Virginia · FDA-approved active Small molecule

Estradiol patch delivers estrogen through the skin to replace or supplement endogenous estrogen levels.

Estradiol patch delivers estrogen through the skin to replace or supplement endogenous estrogen levels. Used for Menopausal vasomotor symptoms (hot flashes, night sweats), Moderate to severe menopausal vulvar and vaginal atrophy, Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.

At a glance

Generic nameEstradiol patch
Also known asVivelle, transdermal17-beta-estradiol, estrofem 2 mg tablet, Novo Nordisk, Bagsvaerd, Denmark, Climara 50 mcg/day, Micronized Estradiol
SponsorUniversity of Virginia
Drug classEstrogen replacement therapy
TargetEstrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
ModalitySmall molecule
Therapeutic areaEndocrinology / Women's Health
PhaseFDA-approved

Mechanism of action

The patch formulation provides transdermal delivery of 17β-estradiol, the primary endogenous estrogen, which binds to estrogen receptors (ERα and ERβ) throughout the body. This activates estrogen-responsive genes involved in reproductive, cardiovascular, bone, and central nervous system function. The transdermal route bypasses first-pass hepatic metabolism, providing more stable hormone levels compared to oral formulations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results